Results 111 to 120 of about 371,644 (221)

Trastuzumab deruxtecan in HER2-positive stomach or gastroesophageal junction cancer: a plain language summary of the DESTINY-Gastric02 study. [PDF]

Future Oncol
Van Cutsem E.
europepmc   +1 more source

Stochastic Nanoscale Biophysical Cues as a Basis for the Induction of Glioblastoma‐Like Transcriptional Programs in Astrocytes

Advanced Science, EarlyView.
Stochastic nanoscale physical cues induce glioblastoma (GBM)‐associated transcriptional traits in naïve astrocytes leading to spontaneous formation of spheroids. Cells within spheroids express activated‐MMP2 and a differential gene expression pattern involving P53 and NOTCH3, providing evidence for a role for changes in brain topography, as observed in
Laurent Starck, Tobias Butelmann, Sabrina Hogan, Melika Sarem, Bernd Heimrich, Ritwick Sawarkar, Marie‐Françoise Ritz, Gregor Hutter, V. Prasad Shastri   +8 more
wiley   +1 more source

Reshaping Clinical Destiny of Silent ALCAPA: Multimodal Imaging-Driven Early Diagnosis and Mandatory Intervention. [PDF]

Clin Case Rep
Cheng Y, Li J, Chen H, Wang X, Ma X, Cao Y.   +5 more
europepmc   +1 more source

Destiny [PDF]

, 2007
Fine, Stephanie
core   +1 more source

The Osteoblastic Microenvironment Determines the Fate of Breast Cancer Cells Disseminated in the Bone Marrow

Advanced Science, EarlyView.
This study revealed how the osteoblastic microenvironment determines the fate of cancer cells disseminated in bone, with a focus on whether they colonize, reside in quiescence, or reactivate from dormancy. Targeting integrin signaling may offer promising strategies for preventing quiescent cancer cells reactivation and bone colonization.
Hong‐Li Wang, Rui Zhang, Xiao‐Min Yue, Jie Zhou, Yu‐Fan Huang, Rong Meng, Yu‐Li Wang, Xiao‐Qing Li   +7 more
wiley   +1 more source

Cancer‐Associated Fibroblasts Functions as Multifunctional Architects of the Tumor Stroma and Represent Emerging Therapeutic Vulnerabilities

Advanced Science, EarlyView.
ABSTRACT Cancer‐associated fibroblasts (CAFs) are the predominant stromal components within the tumor microenvironment (TME), playing multifaceted roles in cancer progression through dynamic interactions with neoplastic and immune cells. Emerging evidence has revealed remarkable heterogeneity and plasticity of CAFs, which originate from diverse ...
Rujiao Liu, Lili Su, Shuiping Gao, Wenting Liu, Hongxia Wang   +4 more
wiley   +1 more source

Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach. [PDF]

Clin Cancer Res
Adesoye T, Dumbrava EE, Raghav KPS, Sahin AA, Chen H, Lee SS, Javle MM, Pant S, Alhalabi O, Le X, Valero V, Pohlmann PR, Meric-Bernstam F.   +12 more
europepmc   +1 more source

Lactylation‐Driven YTHDC1 Alleviates MASLD by Suppressing PTPN22‐Mediated Dephosphorylation of NLRP3

Advanced Science, EarlyView.
In MASLD, YTHDC1 undergoes increased lactylation and ubiquitination, reducing its expression. AARS1 mediates lactylation at lysine 565, while disrupted binding to LDHA further promotes lactylation, suppressing YTHDC1. This downregulation enhances PTPN22 mRNA stability, leading to NLRP3 dephosphorylation and activation, which exacerbates inflammation ...
Feng Zhang, Linghua Zeng, Kunkun Zou, Keying Lin, Fangting Yao, Jinglun Song, Shumeng Zhang, Hanshu Feng, Zhichao Yang, Chunlei Wang, Hongtao Diao, Xue Kong, Tengfei Pan, Joonki Kim, Tianqi Duo, Linqiang Li, Yu Bian   +16 more
wiley   +1 more source

Promoting Treg Polarization‐Mediated Anti‐Scar and Appendage Regeneration in Wound Healing

Advanced Science, EarlyView.
This study develops a PLGA@LA‐BMP4‐PG bilayer scaffold to address scar formation and appendage loss in skin repair. The piezoelectric PLA layer enhances cell migration via electric fields, while GelMA delivers LA promoting Tregs polarization and BMP4 inhibiting FBs differentiation.
Yiwen Yang, Mingjie Kuang, Jiacheng Shi, Ruiyan Li, Yuhan Zhang, Xinting Liu, Runtan Li, Yong Kang, Bin Yao, Shuquan Zhang, Xiaoyuan Ji   +10 more
wiley   +1 more source

Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies. [PDF]

Oncologist
Park YH, Cortes J, Modi S, Hurvitz SA, Bianchini G, Iwata H, Shitara K, Siena S, Goto Y, Ku GY, Powell CA, Swain SM, Arunachalam M, Janek M, Cheng Y, Chu C, Verma P, Kuptsova-Clarkson N, Mathias E, Goodman E, Rugo HS.   +20 more
europepmc   +1 more source